Abstract： Objective To evaluate the high-risk factors for brain metastases after prophylactic cranial irradiation (PCI), and to provide a basis for personalized treatment.Methods A retrospective analysis was performed in 188 patients with limited-stage small-cell lung cancer who received PCI in our hospital from 2005 to 2010. The Kaplan-Meier method was used to calculate the cumulative rate of brain metastases. The log-rank test and the Cox model were used for the univariate and multivariate analyses of the potential factors for the cumulative incidence of brain metastases, respectively.Results In the 188 patients, 31(16.5%) had brain metastases. The 1-, 2-, and 3-year cumulative incidence rates of brain metastases were 4%, 15%, and 20%, respectively. The univariate analysis showed that staged Ⅲ disease before treatment, elevated levels of tumor markers, incomplete remission after chemoradiotherapy, and local-regional relapse were risk factors for high incidence of brain metastases (P=0.044, 0.037, 0.005, 0.007). The multivariate analysis revealed that incomplete remission after chemoradiotherapy and local-regional relapse after chemoradiotherapy were risk factors for high incidence of brain metastases after PCI (P=0.003, 0.040).Conclusions Patients with incomplete remission or local-regional relapse after chemoradiotherapy have high incidence of brain metastases after PCI. For those patients, a frequent follow-up of the central nervous system plus salvage cranial irradiation might provide an alternative to PCI.
Qiu Guoqin,Zhou Xia,Bao Wuan et al. An analysis of risk factors for brain metastases after prophylactic cranial irradiation for limited-stage small-cell lung cancer[J]. Chinese Journal of Radiation Oncology, 2016, 25(10): 1062-1065.
[1] Takada M,Fukuoka M,Kawahara M,et al. Phase Ⅲ study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer:results of the Japan Clinical Oncology Group Study 9104[J].J Clin Oncol,2002,20(14):3054-3060.DOI:10.1200/JCO.2002.12.071. [2] Komaki R,Cox JD,Whitson W.Risk of brain metastasis from small cell carcinoma of the lung related to length of survival and prophylactic irradiation[J].Cancer Treat Rep,1981,65(9-10):811-814. [3] Aupérin A,Arriagada R,Pignon JP,et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic cranial irradiation overview collaborative group[J].New Engl J Med,1999,341(7):476-484.DOI:10.1056/NEJM199908123410703. [4] Le Péchoux C,Dunant A,Senan S,et al. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01,EORTC 22003-08004,RTOG 0212,and IFCT 99-01):a randomised clinical trial[J].Lancet Oncol,2009,10(5):467-474.DOI:10.1016/S1470-2045(09)70101-9. [5] Baas P,Belderbos JS,Senan S,et al. Concurrent chemotherapy (carboplatin,paclitaxel,etoposide) and involved-field radiotherapy in limited stage small cell lung cancer:a Dutch multicenter phase Ⅱ study[J]. Br J Cancer,2006,94(5):625-630.DOI:10.1038/sj.bjc.6602979. [6] Lishner M,Feld R,Payne DG,et al. Late neurological complications after prophylactic cranial irradiation in patients with small-cell lung cancer:the Toronto experience[J]. J Clin Oncol,1990,8(2):215-221. [7] Wong WW,Schild SE,Sawyer TE,et al. Analysis of outcome in patients reirradiated for brain metastases[J]. Int J Radiat Oncol Biol Phys,1996,34(3):585-590.DOI:10.1016/0360-3016(95)02156-6. [8] Lo SSM,Gore EM,Bradley JD,et al. ACR Appropriateness Criteriapre-irradiation evaluation and management of brain metastases[EB/OL].[2015-01-20].https://acsearch.acr.org/docs/69384/Narrative/. [9] Yamamoto M,Serizawa T,Shuto T,et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901):a multi-institutional prospective observational study[J].Lancet Oncol,2014,15(4):387-395.DOI:10.1016/S1470-2045(14)70061-0. [10] Seto T,Takahashi T,Yamanaka T,et al. Prophylactic cranial irradiation (PCI) has a detrimental effect on the overall survival (OS) of patients (pts) with extensive disease small cell lung cancer (ED-SCLC):results of a Japanese randomized phase Ⅲ trial[J].J Clin Oncol,2014,32(15):7503. [11] Ozawa Y,Omae M,Fujii M,et al. Management of brain metastasis with magnetic resonance imaging and stereotactic irradiation attenuated benefits of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer[J].BMC Cancer,2015,15(1):589.DOI:10.1186/s12885-015-1593-2. [12] Manapov F,Kl cking S,Niyazi M,et al. Primary tumor response to chemoradiotherapy in limited-disease small-cell lung cancer correlates with duration of brain-metastasis free survival[J].J Neurooncol,2012,109(2):309-314.DOI:10.1007/s11060-012-0894-4. [13] Rosen ST,Makuch RW,Lichter AS,et al. Role of prophylactic cranial irradiation in prevention of central nervous system metastases in small cell lung cancer:potential benefit restricted to patients with complete response[J].Am J Med,1983,74(4):615-624.DOI:10.1016/0002-9343(83)91019-7. [14] Murray N,Coy P,Pater JL,et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The national cancer institute of Canada clinical trials group[J].J Clin Oncol,1993,11(2):336-344. [15] Coy P,Hodson DI,Murray N,et al. Patterns of failure following loco-regional radiotherapy in the treatment of limited stage small cell lung cancer[J].Int J Radiat Oncol Biol Phys,1994,28(2):355-362.DOI:10.1016/0360-3016(94)90058-2. [16] Skarlos DV,Samantas E,Briassoulis E,et al. Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer:a randomized phase Ⅱ study of the Hellenic Cooperative Oncology Group (HeCOG)[J].Ann Oncol,2001,12(9):1231-1238.DOI:10.1023/A:1012295131640. [17] Spiro SG,James LE,Rudd RM,et al. Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer:a London Lung Cancer Group multicenter randomized clinical trial and meta-analysis[J].J Clin Oncol,2006,24(24):3823-3830.DOI:10.1200/JCO.2005.05.3181.
2016, Vol. 25 
